Literature DB >> 27465594

T wave amplitude in lead aVR as a novel diagnostic marker for cardiac sarcoidosis.

Yoshihiro Tanaka1, Tetsuo Konno2,3, Shohei Yoshida1, Toyonobu Tsuda1, Kenji Sakata1, Hiroshi Furusho1, Masayuki Takamura1, Kenichi Yoshimura4, Masakazu Yamagishi1, Kenshi Hayashi1.   

Abstract

It is vital to identify cardiac involvement (CI) in patients with sarcoidosis as the condition could initially lead to sudden cardiac death. Although the T wave amplitude in lead aVR (TWAaVR) is reportedly associated with adverse cardiac events in various cardiovascular diseases, only scarce data are available concerning the utility of lead aVR in identifying CI in patients with sarcoidosis. We retrospectively investigated the diagnostic values of TWAaVR in patients with sarcoidosis in comparison with conventional electrocardiography parameters such as bundle branch block (BBB). From January 2006 to December 2014, 93 consecutive patients with sarcoidosis were enrolled (mean age, 55.7 ± 15.7 years; male, 31 %; cardiac involvement, n = 26). TWAaVR showed the greatest sensitivity (39 %) and specificity (92 %) in distinguishing between sarcoidosis patients with and without CI, at a cutoff value of -0.08 mV. The diagnostic value of BBB for cardiac involvement was significantly improved when combined with TWAaVR (sensitivity: 61-94 %, specificity: 97-89 %, area under the curve: 0.79-0.92, p = 0.018). Multivariate logistic regression analysis indicated that TWAaVR and BBB were independent electrocardiography parameters associated with CI. In summary, we observed that sarcoidosis patients exhibiting a high TWAaVR were likely to have CI. Thus, the application of a combination of BBB with TWAaVR may be useful when screening for CI in sarcoidosis patients.

Entities:  

Keywords:  Cardiac involvement; Electrocardiogram; Lead aVR; Sarcoidosis

Mesh:

Year:  2016        PMID: 27465594     DOI: 10.1007/s00380-016-0881-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  23 in total

1.  Relationship of ST elevation in lead aVR with angiographic findings and outcome in non-ST elevation acute coronary syndromes.

Authors:  Andrew T Yan; Raymond T Yan; Brian M Kennelly; Frederick A Anderson; Andrzej Budaj; José López-Sendón; David Brieger; Jeanna Allegrone; Gabriel Steg; Shaun G Goodman
Journal:  Am Heart J       Date:  2007-07       Impact factor: 4.749

2.  Index for rating diagnostic tests.

Authors:  W J YOUDEN
Journal:  Cancer       Date:  1950-01       Impact factor: 6.860

3.  The prognostic value of T wave amplitude in lead aVR in males.

Authors:  Swee Y Tan; Gregory Engel; Jonathan Myers; Marcus Sandri; Victor F Froelicher
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-04       Impact factor: 1.468

4.  Associations of positive T wave in lead aVR with hemodynamic, coronary, and left ventricular angiographic findings in anterior wall old myocardial infarction.

Authors:  Kazuhiro Shinozaki; Akira Tamura; Junichi Kadota
Journal:  J Cardiol       Date:  2011-03       Impact factor: 3.159

5.  Clinical characteristics of patients in a case control study of sarcoidosis.

Authors:  R P Baughman; A S Teirstein; M A Judson; M D Rossman; H Yeager; E A Bresnitz; L DePalo; G Hunninghake; M C Iannuzzi; C J Johns; G McLennan; D R Moller; L S Newman; D L Rabin; C Rose; B Rybicki; S E Weinberger; M L Terrin; G L Knatterud; R Cherniak
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

6.  Comparison of (18)F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis.

Authors:  Hiroshi Ohira; David H Birnie; Elena Pena; Jordan Bernick; Brian Mc Ardle; Eugene Leung; George A Wells; Keiichiro Yoshinaga; Ichizo Tsujino; Takahiro Sato; Osamu Manabe; Noriko Oyama-Manabe; Masaharu Nishimura; Nagara Tamaki; Alexander Dick; Carole Dennie; Ran Klein; Jennifer Renaud; Robert A deKemp; Terrence D Ruddy; Benjamin J W Chow; Ross Davies; Renee Hessian; Peter Liu; Rob S B Beanlands; Pablo B Nery
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-11       Impact factor: 9.236

7.  Comparison of cardiac MRI and 18F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complet heart block.

Authors:  Makoto Orii; Kumiko Hirata; Takashi Tanimoto; Shingo Ota; Yasutsugu Shiono; Takashi Yamano; Yoshiki Matsuo; Yasushi Ino; Tomoyuki Yamaguchi; Takashi Kubo; Atsushi Tanaka; Takashi Akasaka
Journal:  Heart Rhythm       Date:  2015-06-22       Impact factor: 6.343

8.  Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction.

Authors:  Yitschak Biton; Ilan Goldenberg; Valentina Kutyifa; Jayson R Baman; Scott Solomon; Arthur J Moss; Barbara Szepietowska; Scott McNitt; Bronislava Polonsky; Wojciech Zareba; Alon Barsheshet
Journal:  J Am Coll Cardiol       Date:  2016-01-26       Impact factor: 24.094

9.  Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.

Authors:  K J Silverman; G M Hutchins; B H Bulkley
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

10.  The prognostic value of positive T-wave in lead aVR in hemodialysis patients.

Authors:  Andrzej Jaroszyński; Anna Jaroszyńska; Janusz Siebert; Wojciech Dąbrowski; Jarosław Niedziałek; Anna Bednarek-Skublewska; Tomasz Zapolski; Andrzej Wysokiński; Wojciech Załuska; Andrzej Książek; Todd T Schlegel
Journal:  Clin Exp Nephrol       Date:  2015-02-28       Impact factor: 2.801

View more
  1 in total

1.  Impact of T wave amplitude in lead aVR on predicting cardiac events in ischemic and nonischemic cardiomyopathy patients with an implantable cardioverter defibrillator.

Authors:  Yoshihiro Tanaka; Tetsuo Konno; Yudai Tamura; Toyonobu Tsuda; Hiroshi Furusho; Masayuki Takamura; Kenji Sakata; Masakazu Yamagishi; Kenshi Hayashi
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-04-25       Impact factor: 1.468

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.